Exelixis Initiates Phase I Trial for Anticancer Compound XL880

Exelixis has initiated a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of XL880, a novel, orally administered, small molecule anticancer compound.

XL880 is a Spectrum Selective Kinase Inhibitor that simultaneously inhibits Met and VEGFR2, two receptor tyrosine kinases that play synergistic roles in promoting tumor growth and angiogenesis.

The Phase I clinical trial is designed as an open-label, single and repeat dose-escalation study and will be conducted in patients with solid tumors for whom there are no available therapies known to prolong survival.